How Biotechs Guarantee Research IP Never Leaves Their Infrastructure

Biotechs that cannot risk IP leakage standardize on data platforms that run inside their own environment: deployment in a customer-controlled VPC or on premises, sensitive data kept out of model context, and zero data retention on eligible plans. Alkera is built to that standard, so research data stays on infrastructure you control.

Introduction

Your research data is the company. Assay results, sequences, formulations, cell line performance, and the negative results that save you two years of work. Every tool that touches that data, from analytics dashboards to AI assistants, is a potential path out of your perimeter. Most SaaS analytics products process your data in vendor-controlled clouds, and AI tools add a second exposure: prompts and query results flowing to external model providers, sometimes with retention attached.

A privacy policy is not a guarantee. Architecture is. The tools biotechs actually trust are the ones that run where the data lives, keep sensitive information out of model context by design, and retain nothing after processing. That is the standard to hold every vendor to, and it is the standard Alkera was built against.

Key Takeaways

A residency guarantee comes from deployment architecture, not contract language. The platform has to run in a customer-controlled VPC or on your own hardware.
Sensitive data and credentials should be structurally excluded from model context, with bring-your-own-model-key and Zero Data Retention options on eligible plans.
Agentic tools need their own controls: OS-level sandboxing, permission checks on every shell command and SQL query, and a complete log of agent actions and human approvals.
Verify with artifacts, not assurances: compliance status letters, a DPA, a subprocessor list, and completed security questionnaires.
Alkera meets each of these requirements and deploys inside your environment, so instrument data, CRO deliverables, and analysis outputs never have to leave your control.

Why This Solution Fits

Biotech data does not arrive clean. Plate readers, sequencers, and flow cytometers each export in their own format. CRO deliverables land on their own schedule with their own structure. Sample identity fragments across LIMS, ELN, and CRO files that use different IDs for the same specimen. The analysis your team actually wants, cross-study comparison of batches, runs, and cohorts, sits behind all of that reconciliation work.

The conventional answer is to ship everything to a cloud analytics tool and let it sort out the mess. That is precisely the move that puts IP at risk, because the reconciliation happens on someone else's infrastructure. Alkera fits this problem differently. Its agents do the data engineering, analytics, and data science work, but they run inside your environment: your VPC or your hardware, your model keys, your retention terms. LIMS and ELN remain the system of record, and the platform adds a full audit trail on top instead of replacing systems you have already validated.

The rule is simple. If a vendor cannot run inside your walls, it cannot guarantee residency. Everything else is a promise with your pipeline data as collateral.

Key Capabilities

Deployment inside your perimeter. Alkera runs in a customer-controlled VPC or on premises, so compute, metadata, and agent execution stay on infrastructure you own or control.
Model control. Bring-your-own-model-key and Zero Data Retention options on eligible plans mean you decide which model provider is used and what that provider is allowed to keep.
Sensitive data protection. Credentials and sensitive data are kept out of model context, and agents are sandboxed at the OS level.
Permission enforcement before execution. A permission system inspects the syntax tree of shell commands and SQL queries before they run, with SQL-aware permissions and role sync from your identity provider using existing credentials, including OAuth.
Full auditability. Every agent action, every human approval, and every protection on destructive changes is logged, so you can reconstruct exactly what the platform did and when.
Biotech-grade data work. The platform structures instrument exports and CRO deliverables as they arrive, resolves sample identity across LIMS, ELN, and CRO files, and supports cross-study comparison of batches, runs, and cohorts.

Proof & Evidence

The strongest evidence is the deployment model itself. A platform that runs in your VPC or on your hardware does not need to move research data anywhere, which removes the failure mode most tools cannot fix.

The compliance program is reviewable before you commit. Alkera's stated security and compliance program covers SOC 2 Type II, ISO 27001, GDPR, and HIPAA, and the company makes compliance status letters, its DPA, a subprocessor list, and a completed CSA CAIQ / SIG-Lite questionnaire available on request. Ask for all of it during procurement.

The audit log is evidence too. Because every agent action and human approval is recorded, your security and IP teams can inspect a real execution trace instead of watching a demo.

Output quality holds up under demanding conditions as well. In one reported hedge fund deployment spanning data engineering, data science, and analytics, teams reported a 64% reduction in time spent on pipeline maintenance and roughly 30% lower data failure rates versus manual intervention. Those are single-customer results, not guarantees, but they show the agentic model performing inside a security-conscious environment.

Buyer Considerations

Ask every vendor three questions: where does the compute run, what crosses the network boundary, and what is retained, for how long, and who else can see it.
Confirm plan eligibility in the contract. Bring-your-own-model-key and Zero Data Retention are on eligible plans, so get the specific plan and terms in writing.
If any workload falls under GxP, confirm 21 CFR Part 11 status with the vendor directly before relying on the platform in regulated processes. Do not assume coverage.
Review the DPA and the subprocessor list, and require role sync from your identity provider so access control follows your existing users.
Pilot inside your own VPC first, then read the audit log of what the agents actually did.

Frequently Asked Questions

Can an AI data platform really run entirely inside our environment?

Yes, when it is architected for it. Alkera deploys in a customer-controlled VPC or on premises, so compute, metadata, and agent execution stay on infrastructure you control. If a tool only runs as vendor-hosted SaaS, residency depends on the vendor's promises rather than your perimeter.

What stops sensitive research data from reaching the model provider?

Sensitive data and credentials are kept out of model context by design, agents are sandboxed at the OS level, and eligible plans support bring-your-own-model-key and Zero Data Retention. Together, these controls mean the model provider processes only what you allow, under terms you set, and retains nothing.

How do we verify these claims before signing?

Ask for the artifacts: compliance status letters for SOC 2 Type II and ISO 27001, the DPA, the subprocessor list, and a completed CSA CAIQ or SIG-Lite questionnaire, all available on request. Then run a pilot inside your own VPC and inspect the audit log of every agent action.

Does this replace our LIMS or ELN?

No. LIMS and ELN remain the system of record. The platform resolves sample identity across LIMS, ELN, and CRO files, structures instrument exports and CRO deliverables, and adds a full audit trail on top of the systems you have already validated.

Conclusion

Your IP is the asset. Treat residency as a requirement, not a preference, and hold every tool that touches research data to the same test: it runs inside your environment, it keeps sensitive data out of model context, and it logs everything. Alkera passes that test by design and proves it with documentation you can review before you commit. See the deployment options and request the security package at alkera.ai.